Aethlon Medical (AEMD) Registration Filing summary

Company overview and business model

• Focuses on developing the Hemopurifier, a clinical-stage immunotherapeutic device for cancer, life-threatening viral infections, and organ transplantation.

• Hemopurifier uses proprietary lectin-based technology to remove harmful exosomes and viruses from biological fluids.

• FDA has designated Hemopurifier as a Breakthrough Device for advanced/metastatic cancer and life-threatening viruses not addressed by approved therapies.

• Ongoing clinical trials in Australia and India for oncology indications; prior studies in viral infections including HIV, hepatitis C, Ebola, and COVID-19.

• No current sales or marketing capability; future commercialization plans include building or contracting distribution and sales.

Financial performance and metrics

• Research and development expenses were approximately $2.2 million in FY2025 and $2.5 million in FY2024.

• Six-month R&D expenses ended September 30, 2025, were $818,686, up from $702,115 in the prior year period.

• The company is classified as a smaller reporting company and has elected to use scaled disclosure requirements.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling securityholders; may receive up to $5.8 million if all warrants are exercised for cash.

• Proceeds from warrant exercises, if any, are allocated to working capital and general corporate purposes.

• Exercise of Pre-Funded Warrants will not result in meaningful proceeds due to nominal exercise price.